In the last two decades, it has been seen the spread of bacteria resistant to multiple antibacterial agents. Multiresistant bacteria are currently considered an emerging global public health problem. Coordinated efforts are required for the development of new therapeutic strategies as well as new antimicrobial agents. Photodynamic therapy (PDT) is a therapeutic modality that relies on photochemical and photophysical processes to induce microbial cells to die. It has been shown to be effective in bacterial and safe lysis in oral cavity use for both dental procedures and oral disinfection. Sore throat is a common complaint in outpatient medical consultations and emergencies. Acute pharyngotonsillitis represents in the population a great source of social disorders such as loss of work force, in addition to leading to the use of antimicrobials in a repeated way. The main etiological agent of pharyngotonsillitis is Streptococcus pyogenes, which can cause suppurative and non-suppurative complications (rheumatic fever, diffuse acute post-streptococcal glomerulenfritis). In addition to S. pyogenes, a number of microorganisms can cause disease, including bacteria and viruses. The conventional treatment of bacterial pharyngotonsillitis consists of the oral administration of antibiotics, which is often inappropriately used in pharyngotonsillitis of other etiologies with potential emergence of resistance. Even in streptococcal pharyngotonsillitis, at least seven days of treatment are required for full response. The present research will be composed of a clinical trial- Treatment of pharyngotonsillitis with photodynamic therapy in adults of the municipality of São Carlos and region. OBJECTIVES: To evaluate the therapeutic efficacy of PDT with curcumin as a coadjutant in the treatment of acute pharyngotonsillitis in adults in the city of São Carlos. MATERIAL AND METHODS: Randomized and controlled clinical trial4with adults in the age group of 18 to 45 years with diagnosis of acute pharyngotonsillitis. Participants will undergo rapid testing for Group A beta-hemolytic streptococcus (EBHGA). Participants with streptococcal pharyngotonsillitis will be divided into two groups: Group A1 = Antibiotic therapy and photodynamic therapy; Group A2 = Antibiotic therapy and placebo of photodynamic therapy. Participants with non-streptococcal pharyngotonsillitis will be divided into two groups: Group B1 = Photodynamic therapy; Group B2 = Place of photodynamic therapy. The therapeutic response will be evaluated in terms of clinical symptoms and microbiological response.
News published in Agência FAPESP Newsletter about the scholarship: